PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.

医学 内科学 实体瘤疗效评价标准 癌症 肿瘤科 中性粒细胞减少症 宫颈癌 肺癌 胃肠病学 毒性 临床研究阶段
作者
Jordi Rodón,Cesar A. Perez,Kit Man Wong,Michael L. Maitland,Frank Tsai,Jordan Berlin,Ken Liao,I‐Ming Wang,Lada Markovtsova,Ira Jacobs,Nora Cavazos,Meng Li,Anthony W. Tolcher
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 3019-3019 被引量:32
标识
DOI:10.1200/jco.2021.39.15_suppl.3019
摘要

3019 Background: Protein arginine methyltransferase 5 (PRMT5) methylates multiple substrates known to be dysregulated in cancer, including components of the spliceosome machinery. PF-06939999 is a selective small-molecule inhibitor of PRMT5. Here we report the safety, PK, PD, and preliminary activity of PF-06939999 in patients (pts) with selected advanced/metastatic solid tumors. Methods: This phase 1 dose escalation trial (NCT03854227) enrolled pts with solid tumor types marked by potential frequent splicing factor mutations, including advanced/metastatic endometrial cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), urothelial cancer, cervical cancer, or esophageal cancer. PF-06939999 monotherapy was continuously administered orally QD or BID in 28-day cycles. A Bayesian Logistic Regression Model was used to inform dose level decisions. Primary objectives were to assess dose limiting toxicities (DLTs), AEs and laboratory abnormalities. Tumor response was assessed using RECIST v1.1. PK and PD were assessed by determining PF-06939999 plasma concentration after dosing and changes in plasma levels of symmetric di-methyl arginine (SDMA), the product of PRMT5 enzymatic activity. Results: 28 pts received PF-06939999 at doses from 0.5-12 mg daily (QD or BID) during dose escalation. Median number of cycles was 2 (range, 1-13). Most were female (54%) with a median age of 61.5 (range, 32-84) y. Median number of prior therapies was 4. Overall, 4/24 (17%) pts reported DLTs: thrombocytopenia (n=2, 6 mg BID); anemia (n=1, 8 mg QD); and neutropenia (n=1, 6 mg QD). Treatment-related AEs occurred in 24 (86%) pts. Most common (≥20%) treatment-related AEs across all cycles were anemia (43%), thrombocytopenia (32%), dysgeusia, fatigue and nausea (29% each). Grade ≥3 treatment-related AEs included anemia (25%), thrombocytopenia (21%), fatigue, neutropenia and lymphocyte count decreased (4% each). One pt (6mg BID) had Grade 4 treatment-related thrombocytopenia. All cytopenias were dose-dependent and reversible with dose modification. No pts discontinued treatment for treatment-related toxicity. There were no treatment-related deaths. Exposure to PF-06939999 increased with doses in the dose range tested. Plasma SDMA was reduced at steady state (58.4-87.5%), indicating robust PD target inhibition. Two pts had confirmed partial response (HNSCC and NSCLC). 6 mg QD was identified as the recommended monotherapy dose for expansion. Conclusions: PF-06939999 showed dose-dependent and manageable toxicities in this phase 1 dose escalation study. Objective tumor responses were observed in pts with HNSCC and NSCLC. Analysis of archival tissue for the presence of splicing factor mutations and other potential predictive biomarkers is ongoing. Enrollment to part 2 dose expansion is ongoing in pts with NSCLC, HNSCC and urothelial cancer. Clinical trial information: NCT03854227.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
量子星尘发布了新的文献求助10
1秒前
demo完成签到,获得积分10
1秒前
MinQi发布了新的文献求助10
2秒前
sciq完成签到,获得积分10
2秒前
3秒前
坚定盈发布了新的文献求助10
4秒前
多走一步发布了新的文献求助10
4秒前
宋晓静完成签到,获得积分10
4秒前
pan完成签到,获得积分10
5秒前
南城不南完成签到 ,获得积分10
6秒前
笨笨友桃发布了新的文献求助10
7秒前
elivsZhou完成签到,获得积分10
8秒前
9秒前
xcx发布了新的文献求助10
9秒前
天地一体完成签到,获得积分10
10秒前
坚定盈完成签到,获得积分10
11秒前
稀里糊涂完成签到 ,获得积分10
11秒前
多走一步完成签到,获得积分10
12秒前
w_完成签到,获得积分10
13秒前
爱听歌依波完成签到 ,获得积分10
13秒前
Leon发布了新的文献求助10
13秒前
gsgg完成签到 ,获得积分20
14秒前
笨笨友桃完成签到,获得积分10
14秒前
在水一方应助Huang采纳,获得10
14秒前
15秒前
16秒前
郭郭要努力ya完成签到 ,获得积分10
17秒前
18秒前
科研通AI2S应助Saint采纳,获得10
18秒前
annafan完成签到,获得积分10
18秒前
19秒前
科目三应助雷桑采纳,获得10
19秒前
少吃顿饭并不难完成签到 ,获得积分10
20秒前
珠珠发布了新的文献求助10
20秒前
20秒前
刘三哥完成签到 ,获得积分10
21秒前
隐形曼青应助leederay采纳,获得10
22秒前
上官若男应助to_ooooo采纳,获得10
22秒前
海阔天空发布了新的文献求助10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066